{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-024283","form_type":"8-K","ticker":"SNWV","cik":"0001417663","company_name":"SANUWAVE Health, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.783374+00:00","generated_at":"2026-06-15T02:20:35.255138+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"SANUWAVE Q1 revenue up 18% to $3.8M; operating loss flat at $2.0M","bullets":["Revenue $3.8M (+18% YoY) within prior guidance; gross margin fell to 67% from 72%.","UltraMist systems sold 28 (+12% YoY); applicator cases 3,641 (+18% YoY).","Operating loss $2.0M, unchanged YoY; no net income/(loss) figure disclosed.","Post-quarter raised ~$1.2M via terms consistent with prior financing; funds not in Q1 statements.","Q2 revenue growth guided to 15-25% YoY, citing improving inventory supply."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-024283","json":"https://secwatch.observer/filing/0001140361-23-024283.json","markdown":"https://secwatch.observer/filing/0001140361-23-024283.md","text":"https://secwatch.observer/filing/0001140361-23-024283.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417663/000114036123024283/0001140361-23-024283-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417663/000114036123024283/brhc20052858_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:20:35.255138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"de5acbaf73e6f3b677767704b741f5f6a5936007","claim":"SANUWAVE Health, Inc. reported first quarter ended March 31, 2023 results: revenue $3.8 million. Guidance reaffirmed.","evidence_excerpt":"SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced 1st quarter 2023 results. For the three-months ended March 31, 2023: • Revenues increased 18% to $3.8 million for Q1 2023 versus $3.2 million for the same period last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417663/000114036123024283/0001140361-23-024283-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$3.8 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}